Similarly, the CTLA-4 inhibitor antibody Ipilimumab was shown to be effective in inducing IL-2 expression as well as in improving NK cell cytotoxicity in a murine model of melanoma, even if the expression of CTLA-4 on NK cells remains controversial [167]. This evidence concerns the gene CTLA4 and melanoma.